Nanotechnology Now - Press Release: Nanotope Founder Dr. Sam Stupp Featured in Fast Company's February Issue

Home > Press > Nanotope Founder Dr. Sam Stupp Featured in Fast Company's February Issue

Nanotope Founder Dr. Sam Stupp Featured in Fast Company's February Issue

Pasadena, CA | Posted on January 28th, 2011

In Fast Company's most recent February issue an article titled "Molecular Healing" profiles the work of Dr. Sam Stupp, founder of Nanotope, Inc., an Arrowhead portfolio company commercializing regenerative medicine technology developed by Dr. Stupp and his colleagues at Northwestern University. The article describes Dr. Stupp's interdisciplinary approach to technology development, marrying materials science and biology to promote healing of neural and other tissues.

A link to this article can be accessed on the News sections of both the Arrowhead and Nanotope websites: www.arrowheadresearch.com/news.html

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

The advertorial mentioned above contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. For example, there can be no assurance that Arrowhead or its subsidiaries will be able to sustain operations for expected periods, that we will be able to achieve or sustain targeted levels of expense reductions or that any of these entities will be successful in obtaining additional funding needed to sustain operations. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements for any reason.

####

About Nanotope
Arrowhead Research Corporation (NASDAQ: ARWR) is an entrepreneurial leader dedicated to advancing its portfolio of medical nanotechnology subsidiaries. Recognizing that our 21st century capability to design drugs, molecule by molecule, holds the key to improving human health and curing disease, Arrowhead identifies, acquires, develops and clinically advances innovative medical treatments for humankind's most devastating diseases. Arrowhead's select portfolio of subsidiaries is developing products that have the potential to address multiple indications in large, existing market opportunities. Through Arrowhead's efficient holding company structure, each subsidiary benefits from strategic synergies and shared resources.

Arrowhead is primarily focused on advancing its two majority owned subsidiaries, Calando Pharmaceuticals, a leader of RNAi systemic delivery technology, and Ablaris, an anti-obesity therapeutics company. Arrowhead also holds minority investments in Nanotope, a regenerative medicine company and Leonardo Biosystems, a multistage drug delivery company.

For more information, please click here

Contacts:
Brandi Floberg
The Piacente Group, Inc.
212-481-2050

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: